welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Cancer Prevention Pharmaceuticals Announces NEJM Publication of Landmark Phase 3 Clinical Trial for Treatment of Familial Adenomatous Polyposis
Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, today announced The New England Journal of Medicine (NEJM) has published results from its landmark FAP-310 Phase 3 clinical trial of CPP-1X/sul as a pharmaco-preventive treatment for adults with familial adenomatous polyposis (FAP).
FAP is a rare genetic disease that if left untreated progresses to colorectal cancer in nearly 100% of patients. Standard of care is surgery as there are no approved drugs for FAP.
The FAP-310 Phase 3 trial compared the performance of the combination of CPP-1X (eflornithine) and sulindac (CPP-1X/sul), to each single agent alone in delaying progression to an FAP-related clinical event, such as surgery. The trial enrolled 171 patients and was conducted over many years where patients received daily treatment for 2-4 years. It was the largest prospective controlled study ever performed in FAP, and the only clinical event driven trial ever conducted.
expertly curated content related to this topic
-
Pharmacotherapy for Inherited Colorectal CancerIMPORTANCE OF THE FIELD : An important r...
-
Coxibs: Pharmacology, Toxicity and Efficacy in Cancer Clinical TrialsThis chapter briefly summarizes the curr...
-
Colon-Specific Delivery of Celecoxib is a Potential Strategy to Improve Toxicological and Pharmacological Properties...In general, colon-specific delivery of a...
-
Multimedia Intervention in Patients With Familial Adenomatous Polyposis (FAP)The goal of this research study is to te...
-
Ursodeoxycholic Acid Counteracts Celecoxib in Reduction of Duodenal Polyps in Patients With Familial Adenomatous Pol...BACKGROUND: Due to prophylactic colecto...
-
A Randomized Controlled Trial of Eicosapentaenoic acid and/or Aspirin For Colorectal Adenoma Prevention During Colon...BACKGROUND: The naturally-occurring ome...
-
Eviendep Reduces Number and Size of Duodenal Polyps in Familial Adenomatous Polyposis Patients With Ileal Pouch-Anal...AIM: To evaluate if 3 mo oral supplemen...